A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Dr Ellen L. Edens joins Ethics Talk to discuss her article, coauthored with Drs Gabriela Garcia Vassallo and Robert Heimer: "How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?”
Dr Donald Egan joins Ethics Talk to discuss his article, coauthored with Drs Adriane M. dela Cruz, Sarah E. Baker, and John Z. Sadler: “When Are ‘Paraphernalia’ Critical Medical Supplies?”
Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”
An ethical case describes the use of a pharmacy's database to market directly to their patients without either patient consent or disclosure of the marketing intent of the materials they received.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.